Phesi partners with Krystelis to boost diversity in clinical trials

Phesi, Krystelis, clinical trial, Collaboration, data analytics, Diversity in clinical trial

Clinical research and analytics specialist Phesi, in collaboration with Krystelis, has introduced a groundbreaking service aimed at enhancing the diversity of participants in clinical trials.

This innovative partnership has given rise to a Diversity, Equity, and Inclusion (DEI) data service, as announced in a press release on September 6th. Leveraging Phesi’s Trial Accelerator platform in conjunction with Krystelis’ writing expertise, this offering is poised to revolutionize the clinical trial landscape.

The primary objective of this new service is to promote diversity right from the planning phase of clinical trials, with a strategic focus on minimizing protocol amendments. These amendments, which can cost up to $500,000 each, often stem from the need to address issues related to diversity and inclusion. By proactively addressing this aspect, the collaboration seeks not only to streamline trial processes but also to align with global DEI regulations set forth by regulatory bodies such as the FDA.

“Our new DEI Data Service was born of a real need for a more innovative solution to address the lack of diversity in clinical trials. Without diverse patient cohorts that accurately reflect the patient population a drug is intended for, we cannot ensure that drugs will be fully safe or effective. It’s clear the industry needs a new approach to deliver more equitable treatments, and our partnership with Krystelis will deliver this. The new service is the latest in our steps to disrupt clinical development and will enable clients to develop smarter trials and deliver faster cures.”

– Dr Gen Li, founder and CEO of Phesi

While the financial terms of this partnership remain undisclosed, it underscores the industry’s commitment to fostering greater inclusivity and diversity within clinical trials. Phesi had previously introduced its AI-driven Trial Accelerator program in October, touting the potential to save clients an average of $7 million per phase 3 trial.

In essence, this initiative signifies a significant step towards making clinical trials more representative of the diverse populations they aim to serve. By addressing these critical issues at the planning stage, the collaboration between Phesi and Krystelis is poised to bring about positive changes that benefit both patients and the broader healthcare community.

“We are pleased to partner with Phesi to bring greater innovation to the issue of diversity in clinical trials. The new service will make the development process easier for sponsors and help them to ensure they are meeting new, more stringent, regulatory requirements. It also has the potential to save sponsors millions of dollars and months of time, enabling them to bring more effective drugs to market, faster.”

– Dr Pooja Phogat, co-founder and co-CEO of Krystelis

Share This News